PURPOSE:

Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of beroctocog alfa in patients of ages ≥12 years previously treated for severe hemophilia A.

MATERIALS AND METHODS:

Seventy subjects received beroctocog alfa as an on-demand treatment for acute hemorrhage.

 

(후략)